Literature DB >> 23857504

The effects of MyD88 deficiency on disease phenotype in dysferlin-deficient A/J mice: role of endogenous TLR ligands.

Kitipong Uaesoontrachoon1, Hee-Jae Cha, Beryl Ampong, Arpana Sali, Jack Vandermeulen, Benjamin Wei, Brittany Creeden, Tony Huynh, James Quinn, Kathleen Tatem, Sree Rayavarapu, Eric P Hoffman, Kanneboyina Nagaraju.   

Abstract

An absence of dysferlin leads to activation of innate immune receptors such as Toll-like receptors (TLRs) and skeletal muscle inflammation. Myeloid differentiation primary response gene 88 (MyD88) is a key mediator of TLR-dependent innate immune signalling. We hypothesized that endogenous TLR ligands released from the leaking dysferlin-deficient muscle fibres engage TLRs on muscle and immune cells and contribute to disease progression. To test this hypothesis, we generated and characterized dysferlin and MyD88 double-deficient mice. Double-deficient mice exhibited improved body weight, grip strength, and maximum muscle contractile force at 6-8 months of age when compared to MyD88-sufficient, dysferlin-deficient A/J mice. Double-deficient mice also showed a decrease in total fibre number, which contributed to the observed increase in the number of central nuclei/fibres. These results indicate that there was less regeneration in the double-deficient mice. We next tested the hypothesis that endogenous ligands, such as single-stranded ribonucleic acids (ssRNAs), released from damaged muscle cells bind to TLR-7/8 and perpetuate the disease progression. We found that injection of ssRNA into the skeletal muscle of pre-symptomatic mice (2 months old) resulted in a significant increase in degenerative fibres, inflammation, and regenerating fibres in A/J mice. In contrast, characteristic histological features were significantly decreased in double-deficient mice. These data point to a clear role for the TLR pathway in the pathogenesis of dysferlin deficiency and suggest that TLR-7/8 antagonists may have therapeutic value in this disease.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Toll-like receptor; degeneration; dysferlin; inflammation; osteopontin; regeneration; single-stranded RNA

Mesh:

Substances:

Year:  2013        PMID: 23857504      PMCID: PMC4071457          DOI: 10.1002/path.4207

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  58 in total

Review 1.  Dysferlinopathies.

Authors:  Anthony A Amato; Robert H Brown
Journal:  Handb Clin Neurol       Date:  2011

Review 2.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

3.  AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration.

Authors:  Yanchao Huang; Steven H Laval; Alexandra van Remoortere; Jacques Baudier; Chriselle Benaud; Louise V B Anderson; Volker Straub; Andre Deelder; Rune R Frants; Johan T den Dunnen; Kate Bushby; Silvère M van der Maarel
Journal:  FASEB J       Date:  2006-12-21       Impact factor: 5.191

4.  Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model.

Authors:  Andrea Farini; Clementina Sitzia; Claire Navarro; Giuseppe D'Antona; Marzia Belicchi; Daniele Parolini; Giulia Del Fraro; Paola Razini; Roberto Bottinelli; Mirella Meregalli; Yvan Torrente
Journal:  Exp Cell Res       Date:  2012-03-23       Impact factor: 3.905

5.  Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice.

Authors:  Renzhi Han; Ellie M Frett; Jennifer R Levy; Erik P Rader; John D Lueck; Dimple Bansal; Steven A Moore; Rainer Ng; Daniel Beltrán-Valero de Bernabé; John A Faulkner; Kevin P Campbell
Journal:  J Clin Invest       Date:  2010-11-08       Impact factor: 14.808

6.  Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation.

Authors:  E M McNally; C T Ly; H Rosenmann; S Mitrani Rosenbaum; W Jiang; L V Anderson; D Soffer; Z Argov
Journal:  Am J Med Genet       Date:  2000-04-10

7.  Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing.

Authors:  Niall J Lennon; Alvin Kho; Brian J Bacskai; Sarah L Perlmutter; Bradley T Hyman; Robert H Brown
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

Review 8.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

9.  Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy.

Authors:  J Liu; M Aoki; I Illa; C Wu; M Fardeau; C Angelini; C Serrano; J A Urtizberea; F Hentati; M B Hamida; S Bohlega; E J Culper; A A Amato; K Bossie; J Oeltjen; K Bejaoui; D McKenna-Yasek; B A Hosler; E Schurr; K Arahata; P J de Jong; R H Brown
Journal:  Nat Genet       Date:  1998-09       Impact factor: 38.330

10.  Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis.

Authors:  Corrado Angelini; Wolfgang Grisold; Vincenzo Nigro
Journal:  Acta Myol       Date:  2011-12
View more
  14 in total

Review 1.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

2.  Myofiber damage precedes macrophage infiltration after in vivo injury in dysferlin-deficient A/J mouse skeletal muscle.

Authors:  Joseph A Roche; Mohan E Tulapurkar; Amber L Mueller; Nico van Rooijen; Jeffrey D Hasday; Richard M Lovering; Robert J Bloch
Journal:  Am J Pathol       Date:  2015-04-25       Impact factor: 4.307

3.  Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle.

Authors:  Aurelia Defour; Sushma Medikayala; Jack H Van der Meulen; Marshall W Hogarth; Nicholas Holdreith; Apostolos Malatras; William Duddy; Jessica Boehler; Kanneboyina Nagaraju; Jyoti K Jaiswal
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

4.  Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy.

Authors:  Christian Giordano; Kamalika Mojumdar; Feng Liang; Christian Lemaire; Tong Li; John Richardson; Maziar Divangahi; Salman Qureshi; Basil J Petrof
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

5.  Coupling of excitation to Ca2+ release is modulated by dysferlin.

Authors:  Valeriy Lukyanenko; Joaquin M Muriel; Robert J Bloch
Journal:  J Physiol       Date:  2017-06-26       Impact factor: 5.182

6.  Toll-like receptor signalling in regenerative myogenesis: friend and foe.

Authors:  Sajedah M Hindi; Ashok Kumar
Journal:  J Pathol       Date:  2016-04-12       Impact factor: 7.996

7.  MyD88 is required for satellite cell-mediated myofiber regeneration in dystrophin-deficient mdx mice.

Authors:  Yann S Gallot; Alex R Straughn; Kyle R Bohnert; Guangyan Xiong; Sajedah M Hindi; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2018-10-01       Impact factor: 6.150

8.  The effects of H3N2 swine influenza virus infection on TLRs and RLRs signaling pathways in porcine alveolar macrophages.

Authors:  Jinqiu Zhang; Jinfeng Miao; Jibo Hou; Chengping Lu
Journal:  Virol J       Date:  2015-04-14       Impact factor: 4.099

9.  Upregulated IL-1β in dysferlin-deficient muscle attenuates regeneration by blunting the response to pro-inflammatory macrophages.

Authors:  Tatiana V Cohen; Gina M Many; Bryan D Fleming; Viola F Gnocchi; Svetlana Ghimbovschi; David M Mosser; Eric P Hoffman; Terence A Partridge
Journal:  Skelet Muscle       Date:  2015-08-07       Impact factor: 4.912

10.  MyD88 promotes myoblast fusion in a cell-autonomous manner.

Authors:  Sajedah M Hindi; Jonghyun Shin; Yann S Gallot; Alex R Straughn; Adriana Simionescu-Bankston; Lubna Hindi; Guangyan Xiong; Robert P Friedland; Ashok Kumar
Journal:  Nat Commun       Date:  2017-11-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.